{"download_date": ["ClinicalTrials.gov processed this data on May 09, 2023"], "link_text": ["Link to the current ClinicalTrials.gov record."], "url": ["https://clinicaltrials.gov/show/NCT05381090"], "org_study_id": [288862.0], "nct_id": ["NCT05381090"], "brief_title": ["Circulating Ghrelin as a Biomarker for Dementia"], "acronym": ["GDEM3"], "official_title": ["Circulating Ghrelin as a Biomarker for Dementia"], "lead_sponsor": [], "collaborator": [], "source": ["Swansea University"], "has_dmc": ["No"], "is_fda_regulated_drug": ["No"], "is_fda_regulated_device": ["No"], "textblock": ["The primary objective of this study will explore whether circulating acyl-ghrelin (AG) and\r\n      unacylated-ghrelin (UAG) are reduced in neurodegenerative disease associated with cognitive\r\n      impairment. It will focus on validating pilot data generated following the analysis of\r\n      Parkinson's disease (PD), Parkinson's disease dementia (PDD) and healthy cohorts (IRAS\r\n      project ID: 250933). In addition to the advantages of study replication we will extend the\r\n      analysis to include two further patient groups that are associated with cognitive\r\n      impairments, namely, Alzheimer's dementia (AD) and dementia with Lewy bodies (DLB). This\r\n      study will increase confidence in the replication of our findings.\r\n\r\n      This will be a cross-sectional study using peripheral venous blood."], "overall_status": ["Recruiting"], "type": ["Actual", "Anticipated", "Anticipated", "Anticipated", "Actual", "Actual"], "start_date": ["August 15, 2022"], "completion_date": ["September 2024"], "primary_completion_date": ["September 2024"], "phase": [], "study_type": ["Interventional"], "has_expanded_access": ["No"], "allocation": ["Non-Randomized"], "intervention_model": ["Parallel Assignment"], "primary_purpose": ["Diagnostic"], "masking": ["Single (Outcomes Assessor)"], "measure": ["Ghrelin ratio in PD and PDD", "Ghrelin ratio in AD and DLB"], "time_frame": ["Through study completion, an average of 1 year", "Through study completion, an average of 1 year"], "description": ["Quantification of circulating ghrelin peptides", "Quantification of circulating ghrelin peptides", "Venous blood collection", "Venous blood collection", "Venous blood collection", "Venous blood collection", "Venous blood collection", "Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake."], "number_of_arms": [5.0], "enrollment": [100.0], "condition": ["Dementia"], "arm_group_label": ["Healthy control", "Parkinson's disease", "Parkinson's disease dementia", "Dementia with Lewy Bodies", "Alzheimer's disease", "Parkinson's disease dementia"], "arm_group_type": ["Active Comparator", "Experimental", "Experimental", "Experimental", "Experimental"], "intervention_type": ["Diagnostic Test"], "intervention_name": ["Venous blood collection"], "criteria": [], "gender": ["All"], "minimum_age": ["60 Years"], "maximum_age": [], "healthy_volunteers": ["Accepts Healthy Volunteers"], "last_name": ["Jeffrey S Davies, BSc, PhD", "Paola A Griffiths", "Kathie Wareham"], "role": ["Principal Investigator"], "affiliation": ["Swansea University"], "phone": [179260.0], "phone_ext": [3849.0], "email": ["resgov@swansea.ac.uk", "kathie.wareham@wales.nhs.uk"], "facility": [], "status": ["Recruiting"], "contact": [], "country": ["United Kingdom"], "verification_date": ["June 2022"], "study_first_submitted": ["May 20, 2021"], "study_first_submitted_qc": ["May 18, 2022"], "study_first_posted": ["May 19, 2022"], "last_update_submitted": ["September 8, 2022"], "last_update_submitted_qc": ["September 8, 2022"], "last_update_posted": ["September 9, 2022"], "responsible_party_type": ["Sponsor"], "mesh_term": ["Dementia"], "sharing_ipd": ["No"]}